Mitochondria: A pathogenic paradigm in hypertensive renal disease

Hypertension

Volumn 65, Issue 2, 2015, Pages 264-270

  Eirin, Alfonso ^a   Lerman, Amir ^a   Lerman, Lilach O ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE;

ANTIHYPERTENSIVE THERAPY; APOPTOSIS; CLINICAL TRIAL (TOPIC); DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; HUMAN; KIDNEY ARTERY STENOSIS; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY STRUCTURE; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL GENOME; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENOVASCULAR HYPERTENSION; REVASCULARIZATION; REVIEW; TARGET CELL; ANIMAL; CEREBROVASCULAR ACCIDENT; FIBROSIS; GENETIC PREDISPOSITION; GENETICS; HEART LEFT VENTRICLE HYPERTROPHY; HYPERTENSION, RENAL; ISCHEMIA; KIDNEY; METABOLISM; MITOCHONDRIAL GENE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REPERFUSION; STENOSIS, OCCLUSION AND OBSTRUCTION; VASCULARIZATION;

ANIMALS; APOPTOSIS; CONSTRICTION, PATHOLOGIC; DNA, MITOCHONDRIAL; FIBROSIS; GENES, MITOCHONDRIAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, RENAL; HYPERTENSION, RENOVASCULAR; HYPERTROPHY, LEFT VENTRICULAR; ISCHEMIA; KIDNEY; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; REPERFUSION; STROKE;

EID: 84921613028     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.04598     Document Type: Review

References (78)

1. O'Rourke B. From bioblasts to mitochondria: ever expanding roles of mitochondria in cell physiology. Front Physiol. 2010;1:7.
2. McFarland R, Taylor RW, Turnbull DM. Mitochondrial disease-its impact, etiology, and pathology. Curr Top Dev Biol. 2007;77:113-155.
3. Collins AJ, Foley RN, Chavers B, et al. US renal data system 2013 annual data report. Am J Kidney Dis. 2014;63:A7.
4. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44:595-601.
5. Eirin A, Lerman LO. Darkness at the end of the tunnel: poststenotic kidney injury. Physiology (Bethesda). 2013;28:245-253.
6. de Cavanagh EM, Toblli JE, Ferder L, Piotrkowski B, Stella I, Inserra F. Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine. Am J Physiol Regul Integr Comp Physiol. 2006;290:R1616-R1625.
7. Zheleznova NN, Yang C, Ryan RP, Halligan BD, Liang M, Greene AS, Cowley AW Jr. Mitochondrial proteomic analysis reveals deficiencies in oxygen utilization in medullary thick ascending limb of Henle in the Dahl salt-sensitive rat. Physiol Genomics. 2012;44:829-842.
8. Jin K, Vaziri ND. Salt-sensitive hypertension in mitochondrial superoxide dismutase deficiency is associated with intra-renal oxidative stress and inflammation. Clin Exp Nephrol. 2014;18:445-452.
9. Szeto HH, Liu S, Soong Y, Wu D, Darrah SF, Cheng FY, Zhao Z, Ganger M, Tow CY, Seshan SV. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol. 2011;22:1041-1052.
10. Singh D, Chander V, Chopra K. Cyclosporine protects against ischemia/ reperfusion injury in rat kidneys. Toxicology. 2005;207:339-347.
11. Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, Pardee JD, Szeto HH. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24:1250-1261.
12. Castaneda MP, Swiatecka-Urban A, Mitsnefes MM, Feuerstein D, Kaskel FJ, Tellis V, Devarajan P. Activation of mitochondrial apoptotic pathways in human renal allografts after ischemiareperfusion injury. Transplantation. 2003;76:50-54.
13. Eirin A, Li Z, Zhang X, Krier JD, Woollard JR, Zhu XY, Tang H, Herrmann SM, Lerman A, Textor SC, Lerman LO. A mitochondrial permeability transition pore inhibitor improves renal outcomes after revascularization in experimental atherosclerotic renal artery stenosis. Hypertension. 2012;60:1242-1249.
14. Fedorova LV, Sodhi K, Gatto-Weis C, Puri N, Hinds TD Jr, Shapiro JI, Malhotra D. Peroxisome proliferator-activated receptor agonist, HPP593, prevents renal necrosis under chronic ischemia. PLoS One. 2013;8:e64436.
15. Eirin A, Ebrahimi B, Zhang X, Zhu XY, Woollard JR, He Q, Textor SC, Lerman A, Lerman LO. Mitochondrial protection restores renal function in swine atherosclerotic renovascular disease. Cardiovasc Res. 2014;103:461-472.
16. Andrews RM, Kubacka I, Chinnery PF, Lightowlers RN, Turnbull DM, Howell N. Reanalysis and revision of the Cambridge reference sequence for human mitochondrial DNA. Nat Genet. 1999;23:147.
17. Wang S, Li R, Fettermann A, Li Z, Qian Y, Liu Y, Wang X, Zhou A, Mo JQ, Yang L, Jiang P, Taschner A, Rossmanith W, Guan MX. Maternally inherited essential hypertension is associated with the novel 4263A>G mutation in the mitochondrial tRNAIle gene in a large Han Chinese family. Circ Res. 2011;108:862-870.
18. Wilson FH, Hariri A, Farhi A, Zhao H, Petersen KF, Toka HR, Nelson-Williams C, Raja KM, Kashgarian M, Shulman GI, Scheinman SJ, Lifton RP. A cluster of metabolic defects caused by mutation in a mitochondrial tRNA. Science. 2004;306:1190-1194.
19. Merante F, Myint T, Tein I, Benson L, Robinson BH. An additional mitochondrial tRNA(Ile) point mutation (A-to-G at nucleotide 4295) causing hypertrophic cardiomyopathy. Hum Mutat. 1996;8:216-222.
20. Valnot I, Kassis J, Chretien D, de Lonlay P, Parfait B, Munnich A, Kachaner J, Rustin P, Rötig A. A mitochondrial cytochrome b mutation but no mutations of nuclearly encoded subunits in ubiquinol cytochrome c reductase (complex III) deficiency. Hum Genet. 1999;104:460-466.
21. Pastores GM, Santorelli FM, Shanske S, Gelb BD, Fyfe B, Wolfe D, Willner JP. Leigh syndrome and hypertrophic cardiomyopathy in an infant with a mitochondrial DNA point mutation (T8993G). Am J Med. Genet. 1994;50:265-271.
22. Lynch DR, Seyer L. Friedreich Ataxia: New findings, new challenges. Ann Neurol. 2014;76:487-488.
23. Kirby DM, McFarland R, Ohtake A, Dunning C, Ryan MT, Wilson C, Ketteridge D, Turnbull DM, Thorburn DR, Taylor RW. Mutations of the mitochondrial ND1 gene as a cause of MELAS. J Med Genet. 2004;41:784-789.
24. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 2001;38:1107-1111.
25. Doroshchuk AD, Postnov AIu, Afanas'eva GV, Budnikov EIu, Postnov IuV. [Decreased ATP-synthesis ability of brain mitochondria in spontaneously hypertensive rats]. Kardiologiia. 2004;44:64-65.
26. Touyz RM, Yao G, Schiffrin EL. c-Src induces phosphorylation and translocation of p47phox: role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:981-987.
27. Grote K, Flach I, Luchtefeld M, Akin E, Holland SM, Drexler H, Schieffer B. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD(P)H oxidase-derived reactive oxygen species. Circ Res. 2003;92:e80-e86.
28. Andrukhiv A, Costa AD, West IC, Garlid KD. Opening mitoKATP increases superoxide generation from complex I of the electron transport chain. Am J Physiol Heart Circ Physiol. 2006;291:H2067-H2074.
29. Navarro A. Mitochondrial enzyme activities as biochemical markers of aging. Mol Aspects Med. 2004;25:37-48.
30. Paradies G, Petrosillo G, Pistolese M, Ruggiero FM. Reactive oxygen species affect mitochondrial electron transport complex I activity through oxidative cardiolipin damage. Gene. 2002;286:135-141.
31. Boveris A, Valdez LB, Zaobornyj T, Bustamante J. Mitochondrial metabolic states regulate nitric oxide and hydrogen peroxide diffusion to the cytosol. Biochim Biophys Acta. 2006;1757:535-542.
32. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171:2029-2050.
33. Baines CP. The molecular composition of the mitochondrial permeability transition pore. J Mol Cell Cardiol. 2009;46:850-857.
34. Niimi K, Yasui T, Hirose M, Hamamoto S, Itoh Y, Okada A, Kubota Y, Kojima Y, Tozawa K, Sasaki S, Hayashi Y, Kohri K. Mitochondrial permeability transition pore opening induces the initial process of renal calcium crystallization. Free Radic Biol Med. 2012;52:1207-1217.
35. Okado-Matsumoto A, Fridovich I. Subcellular distribution of superoxide dismutases (SOD) in rat liver: Cu,Zn-SOD in mitochondria. J Biol Chem. 2001;276:38388-38393.
36. Seifi B, Kadkhodaee M, Karimian SM, Zahmatkesh M, Shams S, Bakhshi E. Reduction of kidney damage by supplementation of vitamins C and E in rats with deoxycorticosterone-salt-induced hypertension. Iran J Kidney Dis. 2009;3:197-202.
37. Vasdev S, Ford CA, Parai S, Longerich L, Gadag V. Dietary vitamin C supplementation lowers blood pressure in spontaneously hypertensive rats. Mol Cell Biochem. 2001;218:97-103.
38. Vasdev S, Gill V, Parai S, Longerich L, Gadag V. Dietary vitamin E supplementation lowers blood pressure in spontaneously hypertensive rats. Mol Cell Biochem. 2002;238:111-117.
39. Keaney JF Jr, Gaziano JM, Xu A, Frei B, Curran-Celentano J, Shwaery GT, Loscalzo J, Vita JA. Low-dose alpha-tocopherol improves and highdose alpha-tocopherol worsens endothelial vasodilator function in cholesterol-fed rabbits. J Clin Invest. 1994;93:844-851.
40. Versari D, Daghini E, Rodriguez-Porcel M, Sattler K, Galili O, Pilarczyk K, Napoli C, Lerman LO, Lerman A. Chronic antioxidant supplementation impairs coronary endothelial function and myocardial perfusion in normal pigs. Hypertension. 2006;47:475-481.
41. Daghini E, Zhu XY, Versari D, Bentley MD, Napoli C, Lerman A, Lerman LO. Antioxidant vitamins induce angiogenesis in the normal pig kidney. Am J Physiol Renal Physiol. 2007;293:F371-F381.
42. Abadir PM, Foster DB, Crow M, Cooke CA, Rucker JJ, Jain A, Smith BJ, Burks TN, Cohn RD, Fedarko NS, Carey RM, O'Rourke B, Walston JD. Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci U S A. 2011;108:14849-14854.
43. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res. 2008;102:488-496.
44. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141-1148.
45. Dikalov SI, Nazarewicz RR, Bikineyeva A, Hilenski L, Lassègue B, Griendling KK, Harrison DG, Dikalova AE. Nox2-induced production of mitochondrial superoxide in angiotensin II-mediated endothelial oxidative stress and hypertension. Antioxid Redox Signal. 2014;20:281-294.
46. Odenbach J, Wang X, Cooper S, Chow FL, Oka T, Lopaschuk G, Kassiri Z, Fernandez-Patron C. MMP-2 mediates angiotensin II-induced hypertension under the transcriptional control of MMP-7 and TACE. Hypertension. 2011;57:123-130.
47. Santos JM, Tewari S, Lin JY, Kowluru RA. Interrelationship between activation of matrix metalloproteinases and mitochondrial dysfunction in the development of diabetic retinopathy. Biochem Biophys Res Commun. 2013;438:760-764.
48. Eirin A, Williams BJ, Ebrahimi B, Zhang X, Crane JA, Lerman A, Textor SC, Lerman LO. Mitochondrial targeted peptides attenuate residual myocardial damage after reversal of experimental renovascular hypertension. J Hypertens. 2014;32:154-165.
49. Ballinger SW. Mitochondrial dysfunction in cardiovascular disease. Free Radic Biol Med. 2005;38:1278-1295.
50. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, Coplon NS, Sun L, Meyer TW. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997;99:342-348.
51. de Cavanagh EM, Piotrkowski B, Basso N, Stella I, Inserra F, Ferder L, Fraga CG. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J. 2003;17:1096-1098.
52. Yao PM, Tabas I. Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway. J Biol Chem. 2001;276:42468-42476.
53. Sanz AB, Santamaría B, Ruiz-Ortega M, Egido J, Ortiz A. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol. 2008;19:1634-1642.
54. Bhaskaran M, Reddy K, Radhakrishanan N, Franki N, Ding G, Singhal PC. Angiotensin II induces apoptosis in renal proximal tubular cells. Am J Physiol Renal Physiol. 2003;284:F955-F965.
55. Ying WZ, Sanders PW. Cytochrome c mediates apoptosis in hypertensive nephrosclerosis in Dahl/Rapp rats. Kidney Int. 2001;59:662-672.
56. Gobé GC, Axelsen RA, Searle JW. Cellular events in experimental unilateral ischemic renal atrophy and in regeneration after contralateral nephrectomy. Lab Invest. 1990;63:770-779.
57. Li T, Zhu Y, Fang Y, Liu L. Determination of the optimal mean arterial pressure for postbleeding resuscitation after hemorrhagic shock in rats. Anesthesiology. 2012;116:103-112.
58. Fang Y, Li T, Fan X, Zhu Y, Liu L. Beneficial effects of activation of PKC on hemorrhagic shock in rats. J Trauma. 2010;68:865-873.
59. Dengjel J, Abeliovich H. Musical chairs during mitophagy. Autophagy. 2014;10:706-707.
60. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552-565.
61. Chade AR. Renovascular disease, microcirculation, and the progression of renal injury: role of angiogenesis. Am J Physiol Regul Integr Comp Physiol. 2011;300:R783-R790.
62. Chade AR, Kelsen S. Renal microvascular disease determines the responses to revascularization in experimental renovascular disease. Circ Cardiovasc Interv. 2010;3:376-383.
63. Lavi R, Zhu XY, Chade AR, Lin J, Lerman A, Lerman LO. Simvastatin decreases endothelial progenitor cell apoptosis in the kidney of hypertensive hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol. 2010;30:976-983.
64. Costa LE, La-Padula P, Lores-Arnaiz S, D'Amico G, Boveris A, Kurnjek ML, Basso N. Long-term angiotensin II inhibition increases mitochondrial nitric oxide synthase and not antioxidant enzyme activities in rat heart. J Hypertens. 2002;20:2487-2494.
65. de Cavanagh EM, Inserra F, Ferder L, Fraga CG. Enalapril and captopril enhance glutathione-dependent antioxidant defenses in mouse tissues. Am J Physiol Regul Integr Comp Physiol. 2000;278:R572-R577.
66. Zhang X, Eirin A, Li ZL, Crane JA, Krier JD, Ebrahimi B, Pawar AS, Zhu XY, Tang H, Jordan KL, Lerman A, Textor SC, Lerman LO. Angiotensin receptor blockade has protective effects on the poststenotic porcine kidney. Kidney Int. 2013;84:767-775.
67. Zhang X, Li ZL, Crane JA, Jordan KL, Pawar AS, Textor SC, Lerman A, Lerman LO. Valsartan regulates myocardial autophagy and mitochondrial turnover in experimental hypertension. Hypertension. 2014;64:87-93.
68. Ziegelhöffer A, Mujkošová J, Ferko M, Vrbjar N, Ravingerová T, Uliná O, Waczulíková I, Ziegelhöffer B. Dual influence of spontaneous hypertension on membrane properties and ATP production in heart and kidney mitochondria in rat: effect of captopril and nifedipine, adaptation and dysadaptation. Can J Physiol Pharmacol. 2012;90:1311-1323.
69. Jesinkey SR, Funk JA, Stallons LJ, Wills LP, Megyesi JK, Beeson CC, Schnellmann RG. Formoterol restores mitochondrial and renal function after ischemia-reperfusion injury. J Am Soc Nephrol. 2014;25:1157-1162.
70. Ryall JG, Schertzer JD, Murphy KT, Allen AM, Lynch GS. Chronic beta2-adrenoceptor stimulation impairs cardiac relaxation via reduced SR Ca2+-ATPase protein and activity. Am J Physiol Heart Circ Physiol. 2008;294:H2587-H2595.
71. Léger B, Koopman R, Walrand S, Gehrig SM, Murphy KT, Lynch GS. Chronic formoterol administration reduces cardiac mitochondrial protein synthesis and oxidative capacity in mice. Int J Cardiol. 2011;146:270-272.
72. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010:CD007893.
73. Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol. 2013;37:602-612.
74. Higdon AN, Benavides GA, Chacko BK, Ouyang X, Johnson MS, Landar A, Zhang J, Darley-Usmar VM. Hemin causes mitochondrial dysfunction in endothelial cells through promoting lipid peroxidation: the protective role of autophagy. Am J Physiol Heart Circ Physiol. 2012;302:H1394-H1409.
75. Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473-481.
76. Chakrabarti AK, Feeney K, Abueg C, Brown DA, Czyz E, Tendera M, Janosi A, Giugliano RP, Kloner RA, Weaver WD, Bode C, Godlewski J, Merkely B, Gibson CM. Rationale and design of the EMBRACE STEMI study: a phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am Heart J. 2013;165:509-514. e7.
77. Cooper CJ, Murphy TP, Cutlip DE, et al; CORAL Investigators. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. 2014;370:13-22.
78. Eirin A, Zhu XY, Urbieta-Caceres VH, Grande JP, Lerman A, Textor SC, Lerman LO. Persistent kidney dysfunction in swine renal artery stenosis correlates with outer cortical microvascular remodeling. Am J Physiol Renal Physiol. 2011;300:F1394-F1401.